Literature DB >> 28337600

Technical note: EnVision™ FLEX improves the detectability of depletions of myoglobin and troponin T in forensic cases of myocardial ischemia/infarction.

Sara Sabatasso1, Catia Pomponio2, Tony Fracasso2.   

Abstract

Immunohistochemistry is a well-established technique used in many research laboratories as well as in clinical diagnostics. The method allows to visualize the expression of proteins in biological tissues, as well as to evaluate this expression semi-quantitatively. For diagnosis, an optimal staining, based on a straightforward protocol, is crucial. In many sudden cardiac death cases, immunohistochemistry is the only tool enabling the diagnosis of myocardial ischemia/infarction, thus the diagnosis of the cause of death. Improvements in immunoreactions are actually possible thanks to optimized detection systems. The recently introduced detection system EnVision Flex™ by Dako allows to dramatically improve (in terms of intensity of the signal and practically absence of background) the visualization of antigens in formalin-fixed paraffin-embedded (FFPE) tissue sections. We tested this method for the detection of myoglobin and troponin T in human postmortem cases of myocardial infarction, as the results obtained by using the « classical » ABC (avidin-biotin complex) method have proven to be sub-optimal, thus rendering any interpretation very difficult, if not impossible.

Entities:  

Keywords:  EnVision™; Forensic pathology; Immunohistochemistry; Myocardial infarction; Myoglobin; Troponin T

Mesh:

Substances:

Year:  2017        PMID: 28337600     DOI: 10.1007/s00414-017-1575-9

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  8 in total

1.  A comparative study on the immunohistochemical detection of early myocardial damage.

Authors:  C Ortmann; H Pfeiffer; B Brinkmann
Journal:  Int J Legal Med       Date:  2000       Impact factor: 2.686

2.  Early markers for myocardial ischemia and sudden cardiac death.

Authors:  Sara Sabatasso; Patrice Mangin; Tony Fracasso; Milena Moretti; Mylène Docquier; Valentin Djonov
Journal:  Int J Legal Med       Date:  2016-07-08       Impact factor: 2.686

3.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

4.  Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction.

Authors:  Peter A Kavsak; Andrew R MacRae; Alice M Newman; Viliam Lustig; Glenn E Palomaki; Dennis T Ko; Jack V Tu; Allan S Jaffe
Journal:  Clin Chim Acta       Date:  2007-01-23       Impact factor: 3.786

5.  Sudden cardiac death and myocardial ischemia indicators: a comparative study of four immunohistochemical markers.

Authors:  Carlo P Campobasso; Alessandro S Dell'Erba; Annalisa Addante; Fiorenza Zotti; Andrea Marzullo; Massimo F Colonna
Journal:  Am J Forensic Med Pathol       Date:  2008-06       Impact factor: 0.921

6.  Immunocytochemical diagnosis of early myocardial ischaemic/hypoxic damage.

Authors:  S Leadbeatter; H M Wawman; B Jasani
Journal:  Forensic Sci Int       Date:  1989-02       Impact factor: 2.395

7.  The application of selected histochemical and immunohistochemical markers and procedures to the diagnosis of early myocardial damage.

Authors:  B Brinkmann; M A Sepulchre; G Fechner
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

8.  Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry.

Authors:  B A Ponder; M M Wilkinson
Journal:  J Histochem Cytochem       Date:  1981-08       Impact factor: 2.479

  8 in total
  2 in total

1.  Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry.

Authors:  Shunsuke Itai; Mika K Kaneko; Yuki Fujii; Shinji Yamada; Takuro Nakamura; Miyuki Yanaka; Noriko Saidoh; Saori Handa; Yao-Wen Chang; Hiroyoshi Suzuki; Hiroyuki Harada; Yukinari Kato
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2017-09-11

2.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.

Authors:  Torsten O Nielsen; Samuel C Y Leung; David L Rimm; Andrew Dodson; Balazs Acs; Sunil Badve; Carsten Denkert; Matthew J Ellis; Susan Fineberg; Margaret Flowers; Hans H Kreipe; Anne-Vibeke Laenkholm; Hongchao Pan; Frédérique M Penault-Llorca; Mei-Yin Polley; Roberto Salgado; Ian E Smith; Tomoharu Sugie; John M S Bartlett; Lisa M McShane; Mitch Dowsett; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2021-07-01       Impact factor: 13.506

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.